SCHEMBL10046491

SCHEMBL10046491

CC(=O)Oc1ccc(C2C3=C(CC(c4ccccc4)CC3=O)OC3=C2C(=O)CC(c2ccccc2)C3)cc1OC(C)=O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.41
ALDH1A1 P00352 7/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
NR3C1 P04150 1/20 0.40
GAA P10253 2/20 0.40
MAPK1 P28482 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
CYP3A4 P08684 1/20 0.39
POLB P06746 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 2/20 0.36
RAB9A P51151 2/20 0.36
PTPN1 P18031 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10046482 0.81 GAA (0.51) ALDH1A1MAPTHTTGAACYP3A4
SCHEMBL10046477 0.78 ALDH1A1 (0.46) ALDH1A1MAPTHTTGAAMAPK1
SCHEMBL10046529 0.76 MEN1 (0.58) ALDH1A1MAPTHTTGAAMAPK1
SCHEMBL10046494 0.73 GAA (0.56) TSHRALDH1A1MAPTHTTGAA
SCHEMBL14904060 0.69 GAA (0.51) TSHRALDH1A1MAPTHTTGAA
SCHEMBL326212 0.69 ALDH1A1 (0.46) ALDH1A1MAPTHTTGAAMEN1
SCHEMBL4163503 0.68 CYP19A1 (0.60) MAPTMAPK1CYP3A4KDM4ERAB9A
SCHEMBL178911 0.67 NR3C1 (0.59) TSHRALDH1A1MAPTNR3C1GAA
SCHEMBL178909 0.66 NR3C1 (0.58) TSHRALDH1A1MAPTNR3C1GAA
SCHEMBL8225508 0.66 NR3C1 (0.58) TSHRALDH1A1MAPTNR3C1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8906416-B2 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders PIERRE FABRE DERMO-COSMETIQUE (FR) 2014-12-09 US disclosed
US-8906416-B2 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders PIERRE FABRE DERMO-COSMETIQUE (FR) 2014-12-09 US disclosed
US-20130108568-A1 XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS PIERRE FABRE DERMO-COSMETIQUE (FR) 2013-05-02 US disclosed
US-20130108568-A1 XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS PIERRE FABRE DERMO-COSMETIQUE (FR) 2013-05-02 US disclosed
WO-2012004390-A1 XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS PIERRE FABRE DERMO-COSMETIQUE (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130108568-A1 XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS ACOX3, CBR3, GALR3 TSHR 988/4885ALDH1A1 1099/4885MAPT 3426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.